Select evidence-based treatments for hematopoietic cell transplant (HCT) patients with cytomegalovirus (CMV) considering newer antiviral medications and guideline recommendations Identify critical limitations to conventional CMV therapies, including side-effect toxicities, that often result in suboptimal outcomes Formulate individualized plans for monitoring and treating HCT patients with CMV, including those with refractory or drug-resistant disease
- Provider:RMEI Medical Education, LLC
- Activity Link: https://rmei.com
- Start Date: 2025-04-04 05:00:00
- End Date: 2025-04-04 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Takeda Pharmaceuticals (Any division) - Amount: 92510.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Jointly Provided
- Registration: Open to all
- Specialty: Infectious Disease, Internal Medicine, Medical Oncology
Subscribe
Login
0 Comments
Oldest